Despite initial teething problems, the number of clinically effective monoclonal antibodies is growing.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?
Cell & Bioscience Open Access 07 October 2019
-
A Rational Approach for Creating Peptides Mimicking Antibody Binding
Scientific Reports Open Access 30 January 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
Carson, D.A. et al. Human lymphocyte hybridomas and monoclonal antibodies. Adv. Immunol. 38, 275–311 (1986).
Morrison, S.L. et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81, 6851–6855 (1984).
Boulianne, G.L. et al. Production of functional chimaeric mouse/human antibody. Nature 312, 643–646 (1984).
Jones, P.T. et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525 (1986).
Reichert, J.M. New biopharmaceuticals in the USA: trends in development and marketing approvals 1995–1999. Trends Biotechnol. 18, 364–369 (2000).
DiMasi, J. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69, 297–307 (2001).
Fox, S. Biopharmaceutical contract manufacturing: meeting increased demand for capacity. (HighTech Business Decisions, Moraga, CA; 2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reichert, J. Monoclonal antibodies in the clinic. Nat Biotechnol 19, 819–822 (2001). https://doi.org/10.1038/nbt0901-819
Issue Date:
DOI: https://doi.org/10.1038/nbt0901-819
This article is cited by
-
Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?
Cell & Bioscience (2019)
-
A Rational Approach for Creating Peptides Mimicking Antibody Binding
Scientific Reports (2019)
-
Equipment characterization to mitigate risks during transfers of cell culture manufacturing processes
Cytotechnology (2016)
-
Implementing high-temperature short-time media treatment in commercial-scale cell culture manufacturing processes
Applied Microbiology and Biotechnology (2014)
-
Structural basis of immunosuppression by the therapeutic antibody daclizumab
Cell Research (2010)